Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
urinary human chorionic gonadotropin + triptorelin
- Development stage
- Unknown
- Lead developer
- Mansoura University
- Modality
- Peptides
- Administration
- Intramuscular, Subcutaneous
01
Overview
This combination therapy is a dual-trigger protocol used for final oocyte maturation in women undergoing controlled ovarian stimulation (COS) for assisted reproductive technologies such as intracytoplasmic sperm injection (ICSI). It consists of urinary human chorionic gonadotropin (uHCG), which acts as a surrogate for the natural luteinizing hormone (LH) surge by binding to the LH/hCG receptor, and a gonadotropin-releasing hormone agonist (GnRHa), specifically triptorelin. The GnRHa induces an endogenous surge of both LH and follicle-stimulating hormone (FSH) from the pituitary gland. This dual approach aims to optimize oocyte maturation, improve oocyte yield, and potentially enhance clinical pregnancy rates compared to a single trigger, particularly in specific patient populations. The protocol was evaluated by Mansoura University to determine if post-trigger serum HCG levels could predict ICSI outcomes.
- Brand names
- Choriomon + Decapeptyl
- Other names
- uHCG + GnRHadual trigger (uHCG + GnRHa)urinary human chorionic gonadotropin + gonadotropin-releasing hormone agonist
02
Targets
LHCGR (Luteinizing hormone/choriogonadotropin receptor)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on urinary human chorionic gonadotropin + triptorelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on urinary human chorionic gonadotropin + triptorelin.